PE20120497A1 - Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 - Google Patents

Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7

Info

Publication number
PE20120497A1
PE20120497A1 PE2011001661A PE2011001661A PE20120497A1 PE 20120497 A1 PE20120497 A1 PE 20120497A1 PE 2011001661 A PE2011001661 A PE 2011001661A PE 2011001661 A PE2011001661 A PE 2011001661A PE 20120497 A1 PE20120497 A1 PE 20120497A1
Authority
PE
Peru
Prior art keywords
cdr2
cdr3
cdr1
seq
heterodimer
Prior art date
Application number
PE2011001661A
Other languages
English (en)
Spanish (es)
Inventor
Hailing Hsu
Lan Foltz
Taruna Arora
Frederick W Jacobsen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20120497A1 publication Critical patent/PE20120497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
PE2011001661A 2009-03-20 2010-03-16 Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 PE20120497A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22

Publications (1)

Publication Number Publication Date
PE20120497A1 true PE20120497A1 (es) 2012-05-14

Family

ID=42224952

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001661A PE20120497A1 (es) 2009-03-20 2010-03-16 Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
PE2016000333A PE20160553A1 (es) 2009-03-20 2010-03-16 Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016000333A PE20160553A1 (es) 2009-03-20 2010-03-16 Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7

Country Status (26)

Country Link
US (6) US8444981B2 (OSRAM)
EP (1) EP2408816B1 (OSRAM)
JP (3) JP5498566B2 (OSRAM)
KR (2) KR101346530B1 (OSRAM)
CN (2) CN103382222B (OSRAM)
AR (1) AR075882A1 (OSRAM)
AU (1) AU2010226814B2 (OSRAM)
CA (2) CA2851737C (OSRAM)
CL (3) CL2011002306A1 (OSRAM)
CO (1) CO6501170A2 (OSRAM)
CR (1) CR20110544A (OSRAM)
EA (1) EA034783B1 (OSRAM)
ES (1) ES2751946T3 (OSRAM)
IL (4) IL214868A (OSRAM)
JO (1) JO3615B1 (OSRAM)
MA (1) MA33213B1 (OSRAM)
MX (4) MX338969B (OSRAM)
MY (2) MY162752A (OSRAM)
NZ (1) NZ595464A (OSRAM)
PE (2) PE20120497A1 (OSRAM)
SG (3) SG10201801337WA (OSRAM)
TN (1) TN2011000433A1 (OSRAM)
TW (2) TWI466681B (OSRAM)
UY (1) UY32501A (OSRAM)
WO (1) WO2010107752A2 (OSRAM)
ZA (1) ZA201107279B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
WO2013078375A2 (en) 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
WO2015129858A1 (ja) * 2014-02-28 2015-09-03 アステラス製薬株式会社 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
MA45695A (fr) 2014-08-22 2019-05-22 Sorrento Therapeutics Inc Protéines de liaison à un antigène qui se lient à cxcr3
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA2994412A1 (en) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
US10654931B2 (en) * 2015-08-11 2020-05-19 Osaka University Antibody
CN109153721A (zh) 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
BR112018068628A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
US12503700B2 (en) 2017-03-14 2025-12-23 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US20200179486A1 (en) 2017-04-28 2020-06-11 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
SMT202300397T1 (it) 2020-02-26 2024-01-10 Vir Biotechnology Inc Anticorpi contro sars-cov-2
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3197930A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
US20250304658A1 (en) * 2021-03-12 2025-10-02 Icahn School Of Medicine At Mount Sinai Neutralizing monoclonal antibodies to bk virus
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
CA2182013C (en) 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002078779A1 (fr) * 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
AU2002254431A1 (en) * 2001-03-27 2002-10-08 M. Eric Gershwin Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
UA87979C2 (ru) * 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
PE20051053A1 (es) * 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Also Published As

Publication number Publication date
IL232008A0 (en) 2014-05-28
JP5775615B2 (ja) 2015-09-09
NZ595464A (en) 2013-08-30
CN103382222A (zh) 2013-11-06
CL2011002306A1 (es) 2012-01-13
EA034783B1 (ru) 2020-03-20
IL214868A0 (en) 2011-11-30
AR075882A1 (es) 2011-05-04
MY184957A (en) 2021-04-30
IL214868A (en) 2015-08-31
HK1168116A1 (en) 2012-12-21
CL2014000400A1 (es) 2014-08-29
US20120183561A1 (en) 2012-07-19
MA33213B1 (fr) 2012-04-02
TW201036626A (en) 2010-10-16
CO6501170A2 (es) 2012-08-15
CR20110544A (es) 2011-12-07
CA2851737A1 (en) 2010-09-23
US20130302354A1 (en) 2013-11-14
CN102388068B (zh) 2015-05-20
IL232009A (en) 2015-11-30
KR20130067314A (ko) 2013-06-21
JP2012520679A (ja) 2012-09-10
US8444981B2 (en) 2013-05-21
IL239965A (en) 2016-10-31
IL232009A0 (en) 2014-05-28
JP2014140372A (ja) 2014-08-07
JP5498566B2 (ja) 2014-05-21
MX2014013424A (es) 2015-07-29
MX338969B (es) 2016-05-06
UY32501A (es) 2010-04-30
IL239965A0 (en) 2015-08-31
JP2015214563A (ja) 2015-12-03
US20100254975A1 (en) 2010-10-07
MX2011009897A (es) 2011-12-08
KR101346530B1 (ko) 2013-12-31
KR20110128948A (ko) 2011-11-30
PE20160553A1 (es) 2016-05-18
MX357213B (es) 2018-06-29
MY162752A (en) 2017-07-14
US9499620B2 (en) 2016-11-22
CA2754113C (en) 2014-08-05
MX357211B (es) 2018-06-29
US8871490B2 (en) 2014-10-28
CN102388068A (zh) 2012-03-21
US20120177662A1 (en) 2012-07-12
US20150086563A1 (en) 2015-03-26
ZA201107279B (en) 2012-12-27
US8454961B2 (en) 2013-06-04
SG10201400798VA (en) 2014-07-30
CA2851737C (en) 2019-01-08
IL232008A (en) 2015-11-30
SG174344A1 (en) 2011-11-28
ES2751946T3 (es) 2020-04-02
WO2010107752A2 (en) 2010-09-23
EP2408816A2 (en) 2012-01-25
CA2754113A1 (en) 2010-09-23
AU2010226814A1 (en) 2011-09-29
CN103382222B (zh) 2016-12-28
TWI466681B (zh) 2015-01-01
EA201171148A1 (ru) 2012-04-30
CL2014000401A1 (es) 2014-08-29
TW201418281A (zh) 2014-05-16
US8454962B2 (en) 2013-06-04
US20170275365A1 (en) 2017-09-28
AU2010226814B2 (en) 2013-05-16
SG10201801337WA (en) 2018-03-28
TWI477511B (zh) 2015-03-21
TN2011000433A1 (en) 2013-03-27
KR101391472B1 (ko) 2014-05-07
WO2010107752A3 (en) 2011-01-20
EP2408816B1 (en) 2019-09-04
JO3615B1 (ar) 2020-08-27
JP5980384B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
PE20120497A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
PE20130206A1 (es) Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
CY1121158T1 (el) Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης
PE20140247A1 (es) Anticuerpos anti-cd38
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
NZ703035A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
PE20181051A1 (es) Anticuerpo anti-epha4
CL2010000470A1 (es) Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo.
NZ631473A (en) Anti-cd52 antibodies
EP4115904A3 (en) Anti-rspo3 antibodies
TH137259A (th) แอนทาโกนิสต์แอนติบอดีที่จำเพาะกับแอลฟา-4-บีตา-7 เฮเทอโรไดเมอร์
UA110783C2 (uk) Антитіла проти рецептора фолієвої кислоти 1, їх імунокон'югати і застосування

Legal Events

Date Code Title Description
FC Refusal